Compare Huntington Ingalls Industries Inc (HII) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs McKesson Corporation — how do they compare? Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 10.4× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.08%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and McKesson Corporation for 74 Days on average.
| HII | MCK | |
|---|---|---|
Market Cap | $10.44B | $108.46B |
Volume | 440,462 | 712,607 |
Sector | Industrials | Health |
52-Week High | $453.73 | $995.69 |
52-Week Low | $257.05 | $725.17 |
Typical Hold Time | 28 Days | 74 Days |
Enterprise Value | $13.37B | $115.00B |
Dividend Yield | 2.08% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $265.02, up 1.67% today, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $5.27 surpassing expectations. Recent contract wins, including a $5.1 billion aircraft carrier overhaul, bolster revenue visibility from a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.78 and P/S of 0.79.
The outlook is supported by robust defense budgets and contract momentum, but technical weakness and mixed analyst sentiment (40.7% buy, 55.6% hold) suggest near-term caution. Key risks include execution on large projects and defense spending cycles. The consensus price target of $363.67 implies significant upside if operational targets are met.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
